interaction with Axin -adenomatous polyposis coli (APC) -glycogen synthase kinase (GSK) 3␤ complex that can phosphorylate
␤-catenin and target it to ubiquitin-mediated proteasomal degradation [10] . However, failure of this degradation in cells may occur as a result of gene mutation in APC, ␤-catenin, axin/conductin, or dysregulation of Wnt ligands [11, 12] . Consequently, the accumulated ␤-catenin in cytoplasm is translocated to the nucleus, where it binds to the transcription factor T-cell factor (Tcf)/lymphoid enhancer factor (Lef) and thereby activates gene transcription [13] . Numerous genes relevant for tumour formation and progression have been identified as targets of ␤-catenin/Tcf [14] . Thus [15, 16] . Activating ␤-catenin mutations have also been found in both diffuse-and intestinal-type gastric cancers [16, 17] and ␤-catenin nuclear localization was reported to occur in approximately one-third of gastric adenocarcinomas [17] . In addition, ␤-catenin mutations and nuclear accumulation are observed during late progression stage of rat stomach adenocarcinoma development [18] . More recently, Lowy et al. [19] 
reported that introduction of mutant ␤-catenin by adenoviral infection enhanced invasiveness and proliferation of infected gastric cancer cells. As URG11 has been shown to activate ␤-catenin in hepatocellular carcinoma cells, it is of great interest to find out whether URG11 is implicated in gastric cancer development and progression by activating ␤-catenin signalling pathway. Here, we reported for the first time that URG11 was highly expressed in gastric cancer tissues compared with adjacent nontumourous tissues, and that URG11 expression was correlated with differentiation grade, TNM stage, as well as lymph node metastasis of gastric cancer. We also revealed that URG11 promoted proliferation and invasiveness of gastric cancer cells at least partially through activation of ␤-catenin/TCF pathway and subsequent up-regulation of cyclinD1 and membrane type 1 matrix metallopeptidase (MT1-MMP).

Materials and methods
Patients and tissue samples
Soft agar clonogenic assay
Anchorage-independent growth was determined by soft agar clonogenic assay described previously [27] . 
Invasion assay
Cell invasion assays were performed as described by others [28] (Fig. 1A) , which was consistent with our previous results [22] . In primary tumour tissues, 69% (69 of 100 patients) had positive staining for URG11, which was significantly higher than 39.0% (16 of 41 patients) in premalignant lesions (P Ͻ 0.01; Fig. 1A b and c) and 20 .8% (11 of 53 patients) in normal gastric mucosae (P Ͻ 0.001; Fig. 1A a) (Fig. 2A) . Thus, the cells stably transfected with URG11-si1 were chosen for further cellular assay. When the growth curves of these cell lines were compared in a medium containing 10% FCS (Fig. 2B) , the curves for SGC7901-siR1 and MKN28-siR1 were significantly lower than control cells (pSilencer3. 1 Fig. 2D, (Fig. 3B and C P Ͻ 0.05 and P Ͻ 0.01, respectively). These data suggested that URG11 had a potential to promote metastasis of gastric cancer. (Fig. 4A  upper panel) . Furthermore, RT-PCR showed that URG11 siRNA reduced the mRNA level of ␤-catenin in SGC7901 and MKN28 cells (Fig. 4A lower panel) (Fig. 4B ). These [30] . Therefore, we sought to determine whether these ␤-catenin target genes could be upregulated by URG11. As shown in Fig. 5B , the protein levels of cyclinD1 and MT1-MMP were markedly down-regulated by URG11 siRNA (Fig. 5C) . We also showed that URG11 had no effect on the expression level of MMP2 and MMP9 proteins that also play important roles in tumour metastasis.
Results
URG11 is overexpressed in gastric cancer tissues
-transfected cells and parental cells). Anchorage-independent growth is one of the important characteristics of in vitro tumour growth. Therefore, we examined whether URG11 knockdown would cause an inhibition of cell growth in soft agar. As shown in Fig. 2C, URG11-si1-transfected SGC7901 and MKN28 cells yielded significantly lower numbers of colonies compared to empty vector-transfected and parental cells (P Ͻ 0.01). Hence, inhibition of URG11 could attenuate gastric cancer cell growth.
To further investigate the mechanisms by which URG11 promotes cell growth, the effect of URG11-si1 on the cell cycle of SGC7901 and MKN28 cells was evaluated by flow cytometry. As seen in
URG11 enhances invasive and in vivo metastatic abilities of gastric cancer cells
SGC7901 and MKN28 cells were demonstrated to have invasive ability to penetrate Matrigel and metastatic ability to metastasize mainly to liver instead of lung and other organs [29]. We then evaluated the specific role of the endogenous URG11 in the invasiveness and metastasis of gastric cancer cells. As shown in Fig. 3A, URG11 siRNA transfection produced a marked inhibition of invasion in SGC7901 and MKN28 cells through Matrigel on transwell assay, with the average inhibiting rate of 41.7% and 47.5%, respectively (P Ͻ 0.01). Tail vein metastatic assay in nude mice was performed to examine the in vivo metastatic potential of SGC7901-siR1 and MKN28-siR1 cells. Compared with control cells transfected with empty vector, intravenous inoculation of SGC7901-siR1 and MKN28-siR1 cells led to significantly less visible tumours in liver surface
URG11 upregulates expression of ␤-catenin in vitro and in vivo
URG11 has been demonstrated to activate ␤-catenin in hepatocellular carcinoma cells, we examined if this applies in gastric cancer cells. First, we measured the total and nuclear protein levels of ␤-catenin in SGC7901-siR1, MKN28-siR1 and control cells. Western blotting showed that the total and nuclear protein of ␤-catenin was markedly downregulated in URG11si1-transfected SGC7901 and MKN28 cells compared with control cells
␤-catenin signalling pathway is involved in URG11-induced growth and invasion of gastric cancer cells
To investigate whether ␤-catenin was required for the promoting effects of URG11 on growth and invasion of gastric cancer cells, SGC7901-siR1 and SGC7901-cont cells were transiently transfected with ␤-catenin-specific or irrelevant siRNA, and the effects on cell proliferation and invasion were determined as before. As shown in Fig. 6A, ␤- [32] . Gene amplification and abnormal expression of cyclinD1 have been described in several human cancers [33] [34] [35] . In addition, cyclinD1 has been previously identified as a target of the ␤-catenin pathway [36] . Our experiment data suggested that URG11 might promote gastric cancer cell proliferation through accelerating G1 to S phase transition in the cell cycle. Moreover, we showed that cyclinD1 expression could be downregulated by URG11 siRNA. These findings suggest that URG11 may use ␤-catenin-cyclinD1 pathway to promote gastric cancer growth.
MT1-MMP is the first discovered member of the membranetype MMPs (MT-MMPs) family and is frequently expressed in a variety of human tumours, including gastric cancer [37] [38] [39] . It was identified as an activator of proMMP-2 and also acts as a processing enzyme for CD44 and collagen I [40] [41] [42] . When overexpressed, MT1-MMP strongly promotes cellular invasion and lymph node metastasis [43, 44] . It has been reported that specific down-regulation of MT1-MMP expression was sufficient to cause significant inhibition of the migration and invasion of tumour cells [45] . Moreover, competitive disruption of MT1-MMP function by dominant negative mutants could prevent the metastatic spread of gastric cancer cells into the peritoneal cavity in vivo [46] . Our present work revealed that knockdown of URG11 led to decreased expression of MT1-MMP. We also demonstrated that the expression of MMP-7 and uPA, both of which are previously described ␤-catenin target genes, were not altered by URG11. Lowy et al. [19] 
